Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis

Abstract

No single-tablet antiretroviral (ARV) regimens (STRs) are approved for patients with human immunodeficiency virus (HIV) and end-stage renal disease (ESRD) on hemodialysis (HD). Based on known pharmacokinetic (PK) properties, abacavir (ABC)/lamivudine (3TC)/dolutegravir (DTG) STR may represent a promising option. This case series presents the safety and efficacy of ABC/3TC/DTG STR in patients with HIV and ESRD on HD. Patients were included if they were HIV-positive, maintained on intermittent HD for ESRD, switched to an ARV regimen containing ABC/3TC/DTG, and had at least one set of virologic data before and after the switch. Average age (±standard deviation) was 59 (±8) years. The majority of patients were cis-gender male and non-Hispanic Black. Only one demonstrated clinically significant resistance at baseline. All were on multiple-tablet regimens prior to the switch. Five patients (83%) achieved undetectable HIV-RNA after the switch while only four patients (46%) were undetectable immediately prior. No decline in immune function was noted. ABC/3TC/DTG STR was well tolerated. Only one patient self-reported an adverse event (nausea), which resolved without drug discontinuation. Based on these data, it appears that ABC/3TC/DTG may be a safe and effective ARV-STR option for patients with HIV and ESRD on HD. A larger trial including a PK analysis is needed to confirm these findings.

Keywords

Combination antiretroviral therapy antiretroviral therapy treatment human immunodeficiency virus acquired immunodeficiency syndrome

Get full access to this article

View all access options for this article.

References

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services, http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (accessed 1 October 2017).

GlaxoSmithKline. Epivir (lamivudine) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2016.

Bohjanen

Johnson

Szczech

et al . Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002; 46: 2387–2392.

Johnson

Verpooten

Daniel

et al . Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998; 46: 21–27.

Izzedine

Launay-Vacher

Deray

Dosage of lamivudine in a haemodialysis patient. Nephron 2000; 86: 553.

Heald

Hsyu

Yuen

et al . Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996; 40: 1514–1519.

van Leeuwen

Lange

Hussey

et al . The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection. AIDS 1992; 6: 1471–1476.

Bouazza

Tréluyer

Ghosn

et al . Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Br J Clin Pharmacol 2014; 78: 847–854.

Chittick

Gillotin

McDowell

et al . Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999; 19: 932–942.

10.

Izzedine

Launay-Vacher

Aymard

et al . Pharmacokinetics of Abacavir in HIV-1-infected patients with impaired renal function. Nephron 2001; 89: 62–67.

11.

Yuen

Weller

Pakes

A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47: 351–371.

12.

McDowell

Chittick

Ravitch

et al . Pharmacokinetics of [¹⁴C] abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855–2861.

13.

GlaxoSmithKline. Ziagen (abacavir) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2017.

14.

Castellino

Moss

Wagner

et al . Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother 2013; 57: 3536–3546.

15.

Moltó

Graterol

Miranda

Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother 2016; 60: 2564–2566.

16.

Bollen

Rijnders

Teulen

et al . Dolutegravir is not removed during hemodialysis. AIDS 2016; 30: 1490–1491.

17.

GlaxoSmithKline. Tivicay (dolutegravir) (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2017.

18.

HIV drug interactions. University of Liverpool, www.hiv-druginteractions.org (accessed 1 October 2017).

19.

Schouten

Wit

Stolte

et al. ; The AGEhIV Cohort Study. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals. Clin Infect Dis 2014; 59: 1787–1797.

20.

Razzak Chaudhary

Workeneh

Montez-Rath

et al . Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant 2015; 30: 1734–1740.

21.

Mason

Polypharmacy and medication-related complications in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2011; 20: 492–497.

22.

Ghimire

Castelino

Lioufas

et al . Nonadherence to medication therapy in haemodialysis patients: a systematic review. PloS One 2015; 10: e0144119.

23.

Chesney

Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30: S171–S176.

24.

Clay

Nag

Graham

et al . Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine 2015; 94: e1677.

25.

Yager

Faragon

McGuey

et al . Relationship between single tablet antiretroviral regimen and adherence to antiretroviral and non-antiretroviral medications among veterans’ affairs patients with human immunodeficiency virus. AIDS Patient Care STDS 2017; 31: 370–376.

26.

Bonnet

Bonarek

Morlat

et al . Risk factors for lactic acidosis in HIV‐infected patients treated with nucleoside reverse‐transcriptase inhibitors: a case‐control study. Clin Infect Dis 2003; 36: 1324–1328.